Trends in discovery of new drugs for tuberculosis therapy (Q38237221)

31 August 2017

title

Trends in discovery of new drugs for tuberculosis therapy (English)

1 reference

31 August 2017

1 reference

Maria Rosalia Pasca

0 references

Giovanna Riccardi

0 references

6 August 2014

1 reference

The Journal of Antibiotics

31 August 2017

published in

1 reference

31 August 2017

1 reference

31 August 2017

1 reference

31 August 2017

page(s)

655-659

1 reference

Epidemiology: A mortal foe.

31 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FJA.2014.109

Multi-drug-resistant tuberculosis in HIV positive patients in Eastern Europe

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2014.109

New drugs for the treatment of tuberculosis: needs, challenges, promise, and prospects for the future

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2014.109

Resistance in tuberculosis: what do we know and where can we go?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2014.109

In vitrosusceptibility testing and totally drug-resistant tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2014.109

Totally drug-resistant tuberculosis in India.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2014.109

Emergence of new forms of totally drug-resistant tuberculosis bacilli: super extensively drug-resistant tuberculosis or totally drug-resistant strains in iran.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2014.109

Totally drug-resistant and extremely drug-resistant tuberculosis: the same disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2014.109

Mycobacterium tuberculosis: drug resistance and future perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2014.109

The mechanism of isoniazid killing: clarity through the scope of genetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2014.109

Triclosan as a substrate and inhibitor of 3'-phosphoadenosine 5'-phosphosulfate-sulfotransferase and UDP-glucuronosyl transferase in human liver fractions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2014.109

Triclosan Derivatives: Towards Potent Inhibitors of Drug-Sensitive and Drug-ResistantMycobacterium tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2014.109

Towards a new tuberculosis drug: pyridomycin - nature's isoniazid

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2014.109

Sequence and Structural Convergence of Broad and Potent HIV Antibodies That Mimic CD4 Binding

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2014.109

Ribosomal protein S1 influences trans-translation in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2014.109

Mode of action of pyrazinamide: disruption of Mycobacterium tuberculosis membrane transport and energetics by pyrazinoic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2014.109

Microbial persistence. I. The capacity of tubercle bacilli to survive sterilization in mouse tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2014.109

Biosynthesis of D-arabinose in mycobacteria - a novel bacterial pathway with implications for antimycobacterial therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2014.109

The emb operon, a gene cluster of Mycobacterium tuberculosis involved in resistance to ethambutol.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2014.109

Detection of rifampicin-resistance mutations in Mycobacterium tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2014.109

History of the Development of Rifampin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2014.109

The RNA polymerase "switch region" is a target for inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2014.109

New approaches to target the mycolic acid biosynthesis pathway for the development of tuberculosis therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2014.109

Advances in the development of new tuberculosis drugs and treatment regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2014.109

Tuberculosis clinical trial update and the current anti-tuberculosis drug portfolio

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2014.109

Treatment of pulmonary tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2014.109

Bedaquiline: First FDA-approved tuberculosis drug in 40 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2014.109

A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2014.109

A review of tuberculosis: Focus on bedaquiline

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2014.109

Selectivity of TMC207 towards mycobacterial ATP synthase compared with that towards the eukaryotic homologue

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2014.109

Bedaquiline: a novel diarylquinoline for multidrug-resistant tuberculosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2014.109

PA-824 kills nonreplicating Mycobacterium tuberculosis by intracellular NO release

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2014.109

The mechanism of action of PA-824: Novel insights from transcriptional profiling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2014.109

Early bactericidal activity and pharmacokinetics of PA-824 in smear-positive tuberculosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2014.109

Delamanid for multidrug-resistant pulmonary tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2014.109

Clinical benefit of delamanid (OPC-67683) in the treatment of multidrug-resistant tuberculosis patients in China

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2014.109

Rifapentine for the treatment of pulmonary tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2014.109

An update on the use of rifapentine for tuberculosis therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2014.109

Safety and pharmacokinetics of escalating daily doses of the antituberculosis drug rifapentine in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2014.109

SQ109 targets MmpL3, a membrane transporter of trehalose monomycolate involved in mycolic acid donation to the cell wall core of Mycobacterium tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2014.109

Discovery and development of SQ109: a new antitubercular drug with a novel mechanism of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2014.109

The Mycobacterium tuberculosis secreted protein Rv0203 transfers heme to membrane proteins MmpL3 and MmpL11.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2014.109

Inhibition of mycolic acid transport across the Mycobacterium tuberculosis plasma membrane

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2014.109

MmpL3 is the cellular target of the antitubercular pyrrole derivative BM212

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2014.109

Identification of novel inhibitors of M. tuberculosis growth using whole cell based high-throughput screening.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2014.109

Indoleamides are active against drug-resistant Mycobacterium tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2014.109

Structure, function and inhibition of RND efflux pumps in Gram-negative bacteria: an update.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2014.109

Improved BM212 MmpL3 inhibitor analogue shows efficacy in acute murine model of tuberculosis infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2014.109

The DprE1 enzyme, one of the most vulnerable targets of Mycobacterium tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2014.109

Benzothiazinones kill Mycobacterium tuberculosis by blocking arabinan synthesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2014.109

Structural Basis for Benzothiazinone-Mediated Killing of Mycobacterium tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2014.109

Clinical isolates of Mycobacterium tuberculosis in four European hospitals are uniformly susceptible to benzothiazinones

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2014.109

In vitro combination studies of benzothiazinone lead compound BTZ043 against Mycobacterium tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2014.109

Towards a new combination therapy for tuberculosis with next generation benzothiazinones

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2014.109

High content screening identifies decaprenyl-phosphoribose 2' epimerase as a target for intracellular antimycobacterial inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2014.109

Leads for antitubercular compounds from kinase inhibitor library screens

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2014.109

Identification of a small molecule with activity against drug-resistant and persistent tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2014.109

Azaindoles: noncovalent DprE1 inhibitors from scaffold morphing efforts, kill Mycobacterium tuberculosis and are efficacious in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2014.109

Structural basis of inhibition of Mycobacterium tuberculosis DprE1 by benzothiazinone inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2014.109

Vaccine development for tuberculosis: current progress

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2014.109

Global tuberculosis control: lessons learnt and future prospects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2014.109

7 January 2021

Synthesis of 3-heteryl substituted pyrrolidine-2,5-diones via catalytic Michael reaction and evaluation of their inhibitory activity against InhA and Mycobacterium tuberculosis

1 reference

https://api.crossref.org/works/10.1038%2FJA.2014.109

7 January 2021

Characterization of pncA mutations in pyrazinamide-resistant Mycobacterium tuberculosis

1 reference

https://api.crossref.org/works/10.1038%2FJA.2014.109

7 January 2021

Pyrazinamide inhibits trans-translation in Mycobacterium tuberculosis

1 reference

https://api.crossref.org/works/10.1038%2FJA.2014.109

7 January 2021

Approaches to the development of new antituberculosis drugs

1 reference

https://api.crossref.org/works/10.1038%2FJA.2014.109

7 January 2021

Identifiers

DOI

10.1038/JA.2014.109

1 reference

Dimensions Publication ID

31 August 2017

1025924297

0 references

1 reference